1

2	nearby community residents, North Carolina, USA, 2021-2022
3	Carolyn Gigot <sup>a</sup> #, Nora Pisanic <sup>a</sup> , Kate Kruczynski <sup>a</sup> , Magdielis Gregory Rivera <sup>a</sup> , Kristoffer Spicer <sup>a</sup> ,

SARS-CoV-2 antibody prevalence among industrial livestock operation workers and

- 4 Kathleen M. Kurowski<sup>a</sup>, Pranay Randad<sup>a</sup>, Kirsten Koehler<sup>a</sup>, William A. Clarke<sup>b</sup>, Phyla Holmes<sup>c</sup>,
- 5 DJ Hall, Jr.<sup>c</sup>, Devon Hall, Sr.<sup>c</sup>, Christopher D. Heaney<sup>a,d,e</sup>#
- 6

- 7 <sup>a</sup>Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of
- 8 Public Health, Baltimore, Maryland, USA
- 9 <sup>b</sup>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland,
- 10 USA
- 11 <sup>c</sup>Rural Empowerment Association for Community Help, Warsaw, North Carolina, USA
- <sup>d</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
- 13 Maryland, USA
- <sup>14</sup> <sup>e</sup>Department of International Health, Johns Hopkins Bloomberg School of Public Health,
- 15 Baltimore, Maryland, USA
- 16
- 17 Running Head: SARS-CoV-2 IgG: livestock workers and nearby residents
- 18
- 19 #Address correspondence to Carolyn Gigot, cgigot1@jhu.edu and Christopher D. Heaney,
- 20 <u>cheaney1@jhu.edu</u>
- 21
- 22 \*Present address: Magdielis Gregory Rivera, Amentum, Falls Church, Virginia, USA.
- 23 \*Present address: Pranay Randad, Flagship Pioneering, Cambridge, Massachusetts, USA.
- Abstract word count: 347
- 25 Main text word count: 3663 (without Materials and Methods, References, tables, or figure
- 26 legends)

2

# 27 ABSTRACT

Industrial livestock operations (ILOs), particularly processing facilities, emerged as 28 29 centers of coronavirus disease 2019 (COVID-19) outbreaks in spring 2020. Confirmed cases of 30 COVID-19 underestimate true prevalence. To investigate prevalence of antibodies against 31 SARS-CoV-2, we enrolled 279 participants in North Carolina from February 2021 to July 2022: 32 90 from households with at least one ILO worker (ILO), 97 from high-ILO intensity areas (ILO 33 neighbors - ILON), and 92 from metropolitan areas (Metro). Participants provided a saliva swab 34 we analyzed for SARS-CoV-2 IgG using a multiplex immunoassay. Prevalence of infection-35 induced IgG (positive for nucleocapsid and receptor binding domain) was higher among ILO 36 (63%) compared to ILON (42.9%) and Metro (48.7%) participants (prevalence ratio [PR] =1.38; 37 95% confidence interval [CI]: 1.06, 1.80; ref. ILON and Metro combined). Prevalence of 38 infection-induced IgG was also higher among ILO participants compared to an Atlanta 39 healthcare worker cohort (PR=2.45, 95% CI: 1.8, 3.3) and a general population cohort in North 40 Carolina (PRs 6.37-10.67). Infection-induced IgG prevalence increased over the study period. 41 Participants reporting not masking in public in the past two weeks had higher infection-induced 42 IgG prevalence (78.6%) compared to participants reporting masking (49.3%) (PR=1.59; 95% CI: 43 1.19, 2.13). Lower education, more people per bedroom, Hispanic/Latino ethnicity, and more 44 contact with people outside the home were also associated with higher infection-induced IgG 45 prevalence. Similar proportions of ILO (51.6%), ILON (48.4%), and Metro (55.4%) participants 46 completed the COVID-19 primary vaccination series; median completion was more than four 47 months later for ILO compared to ILON and Metro participants.

48

#### 49 Importance

50 Few studies have measured COVID-19 seroprevalence in North Carolina, especially 51 among rural, Black, and Hispanic/Latino communities that have been heavily affected. Antibody 52 results show high rates of COVID-19 among industrial livestock operation workers and their

53	household members. Antibody results add to evidence of health disparities in COVID-19 by
54	socioeconomic status and ethnicity. Associations between masking and physical distancing with
55	antibody results also add to evidence of the effectiveness of these prevention strategies. Delays
56	in the timing of receipt of COVID-19 vaccination reinforce the importance of dismantling
57	vaccination barriers, especially for industrial livestock operation workers and their household
58	members.
59	
60	KEYWORDS
61	COVID-19, SARS-CoV-2; seroprevalence; industrial livestock operations; health disparities
62	
63	ACKNOWLEDGEMENTS
64	This study was supported by an anonymous gift, the JHU COVID-19 Research and
65	Response Program, the FIA Foundation, and NIAID R21 R21AI139784. C.G., K.M.K., K.
66	Koehler, and C.D.H. were supported by NIOSH ERC T42 OH0008428. Additionally, N.P., K.
67	Kruczynski, M.G.R., K.S., and C.D.H. were supported by an anonymous gift, the JHU COVID-19
68	Research and Response Program, and the FIA Foundation. The C3PI Study was funded by
69	research grants to Duke University from the NCDHHS and the Center for Disease Control and
70	Prevention (CDC). The MURDOCK Study was funded by a gift from the David H. Murdock
71	Institute for Business and Culture and is supported by Duke's NIH National Center for
72	Advancing Translational Sciences (NCATS) Clinical and Translational Science Award (CTSA)
73	UL1TR002553. Additional support was provided by the Duke Claude D. Pepper Older
74	Americans Independence Center Grant, 5P30AG028716-15.
75	We thank the community organizers at the Rural Empowerment Association for
76	Community Help (REACH), especially Margaret Carr, Clesha Hall, Unique Hall, Angela
77	Matthews, Arika Miller, and Helen Santizo, as well as all participants, without whom this study
78	would not have been possible. We acknowledge Caryn Kok and Eric Xu for assistance with

4

antibody testing. We also acknowledge Dr. Matthew H. Collins for sharing antibody prevalence
data from the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study and Douglas
Wixted and Dr. L. Kristin Newby for sharing antibody prevalence data from the C3PI Study.

---

## 83 INTRODUCTION

84 North Carolina is the second largest hog, third largest turkey, and fourth largest broiler chicken producing state (1). Animal slaughtering and processing workers have more than twice 85 86 the rate of injury and illness (6.7 per 100 full-time equivalents) and animal production workers 87 close to twice the rate of injury and illness (5.2 per 100 full-time equivalents) compared to all US 88 workers (2.9 per 100 full-time equivalents), despite reporting exemptions and other factors likely 89 resulting in injury and illness undercounts (2-5). Hog and poultry production have also been 90 associated with a range of adverse health outcomes among nearby community residents, 91 including respiratory health problems and infectious diseases (6–8). Since winter 2019, COVID-92 19 has become a health hazard associated with working at or living near industrial livestock 93 operations (ILOs). Tens of thousands of cases of COVID-19 have been associated with working 94 at meat and poultry processing facilities (9–11). Taylor et al. found an association between 95 county livestock processing plants and county COVID-19 incidence, estimating as many as 8% 96 of US cases through summer 2020 could be linked to processing plants (12). High numbers of 97 COVID-19 cases have also been associated with food processing, food manufacturing, and 98 agricultural workplaces more broadly (13). COVID-19 has disproportionately burdened low 99 income communities of color (14–16). Disparities by race and ethnicity are also evident among 100 livestock processing and agricultural workers (10, 13).

Given limited access to SARS-CoV-2 molecular testing, particularly for asymptomatic or mild COVID-19 cases, and limitations in molecular test reporting, SARS-CoV-2 antibody testing represents an attractive strategy to estimate COVID-19 prevalence, attack rates, and population immunity due to prior infection and/or vaccination (17, 18). SARS-CoV-2 antibodies in oral fluid

5

(hereafter, salivary) have been shown to correspond to SARS-CoV-2 antibodies present in
blood and to differentiate between PCR-confirmed cases and pre-COVID-19 samples with high
sensitivity and specificity (19–21). Compared to blood collection, saliva collection is painless,
safe, and readily self-collected at home and mailed to a testing lab. However, saliva has been
less frequently used for surveillance (20, 22).

We used a salivary multiplex immunoassay targeting IgG responses to SARS-CoV-2 nucleocapsid (N), receptor-binding domain (RBD), and spike (S) protein to differentiate between infection-induced versus infection- and/or vaccination-induced immune response. Infection induces antibodies against all proteins, while the mRNA (Pfizer-BioNTech, Moderna), Janssen (Johnson & Johnson), and Novavax vaccines currently approved for use in the United States induce RBD- and S-specific antibodies only (23). Accordingly, individuals testing positive for both SARS-CoV-2 N and RBD IgG likely experienced infection (24).

117 In this study, we measured salivary SARS-CoV-2 IgG prevalence in a cohort of North 118 Carolina households enrolled in collaboration with REACH (Rural Empowerment Association for 119 Community Help), a community group based in Duplin County, North Carolina. We aimed to (a) 120 compare infection-induced IgG prevalence between participants living in households with at 121 least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal 122 rendering plant (industrial livestock operation household group – ILO), participants living nearby 123 these facilities without any known occupational exposure to livestock (ILO neighbors – ILON). 124 and participants living in metropolitan areas of North Carolina (Metro); (b) identify risk factors for 125 infection-induced IgG prevalence within our study population; and (c) compare infection-induced 126 IgG prevalence between ILO participants and a cohort of other high-risk occupation workers 127 sampled using the same assay, as well as a general population-representative cohort in North 128 Carolina.

6

## 130 **RESULTS**

## 131 *Participant characteristics*

132 A total of 279 individuals from 240 households (80 ILO, 80 ILON, and 80 Metro) 133 participated (Table 1). ILON participants were generally enrolled earliest, with a median 134 interview date of June 6, 2021, followed by Metro participants (median August 18, 2021), and 135 ILO participants (median February 9, 2022). Overall, ILON participants were older than ILO and 136 Metro participants. Roughly half of ILO and ILON participants were female, compared to 72.8% 137 of Metro participants. Most participants in all groups were Black; more Metro participants were 138 White and fewer were Hispanic/Latino compared to ILO and ILON participants. Education level 139 differed between groups: most ILO participants had a high school education or lower, while 140 most Metro participants had post-high school education. Most participants lived in homes with 141 one or fewer household members per bedroom, although ILO participants reported more 142 household members per bedroom compared to ILON and Metro participants. The majority of 143 participants reported that their household's primary health care provider was a private doctor or 144 clinic. However, more ILON (15.5%) compared to ILO (13.3%) and Metro (8.7%) participants 145 reported not having health insurance. More than twice as many ILO participants (91.1%) 146 reported working in person compared to ILON (42.3%) and Metro (40.2%) participants.

147

## 148 **Table 1.** Participant characteristics by study group

Characteristic	ILO n=90		ILON n=97		Metro n=92	
	(80 hou	iseholds)	(80 hou	iseholds)	(80 hou	seholds)
Sampling date, median	2/9/2022	(4/2/2021-	6/6/2021	(3/8/2021-	8/18/2021	(2/23/2021-
(range)		7/18/2022)		6/3/2022)		6/7/2022)

Age in years, median	41.5	(13-67)	50	(5-83)	37	(9-74)
(range)						
Gender, n (%)						
Female	47	(52.2)	54	(55.7)	67	(72.8)
Male	43	(47.8)	42	(43.3)	25	(27.2)
No response	0	(0)	1	(1)	0	(0)
Race/ethnicity, n (%)						
Black/African	79	(87.8)	83	(85.6)	74	(80.4)
American						
Hispanic/Latino	8	(8.9)	11	(11.3)	3	(3.3)
White/Caucasian	1	(1.1)	1	(1)	8	(8.7)
Both Black and	0	(0)	1	(1)	2	(2.2)
White						
Asian-American	0	(0)	0	(0)	1	(1.1)
Other or no	2	(2.2)	1	(1)	3	(3.3)
response						
Education, n (%)						
High school	65	(71.4)	53	(54.6)	37	(40.2)
diploma/GED or less						
Post-high school	26	(28.6)	42	(43.3)	53	(57.6)
No response	0	(0)	2	(2.2)	2	(2.2)
	l		I		l	

Household members,	2.7	(1.4)	2.1	(1.3)	2.2	(1.2)
mean (SD)						
Household members	1	(0.5)	0.8	(0.4)	0.9	(0.5)
nor bodroom, moon	I	(0.0)	0.0	(0.+)	0.0	(0.0)
(50)						
Primary healthcare						
provider, n (%) <sup>a</sup>						
Private doctor's	56	(62.2)	55	(56.7)	54	(58.7)
office or clinic						
Urgent care	15	(16.7)	23	(23.7)	17	(18.5)
Emergency room	14	(15.6)	11	(11.3)	13	(14.1)
Hospital	10	(11.1)	13	(13.4)	8	(8.7)
Free clinic	6	(6.7)	7	(7.2)	5	(5.4)
Company clinic,	6	(6.7)	1	(1)	5	(5.4)
doctor, or nurse						
Do not use medical	2	(2.2)	1	(1)	0	(0)
care						
Health insurance, n (%) <sup>a</sup>						
Company health	30	(33.3)	33	(34)	56	(60.9)
insurance plan						
Public health	34	(37.8)	35	(36.1)	17	(18.5)
insurance						

9

Private health	15	(16.7)	16	(16.5)	10	(10.9)
insurance						
No health insurance	12	(13.3)	15	(15.5)	8	(8.7)
Other or no	2	(2.2)	0	(0)	1	(1.1)
response						
Work or attend school or	85	(94.4)	44	(45.4)	41	(44.6)
childcare outside the						
home, n (%)						
Work (in person)	82	(91.1)	41	(42.3)	37	(40.2)
only						
Attend school only	2	(2.2)	3	(3.1)	3	(3.3)
Work and attend	0	(0)	0	(0)	1	(1.1)
school						
Attend childcare	1	(1.1)	0	(0)	0	(0)
Do not work or attend	5	(5.6)	53	(54.6)	51	(55.4)
school or childcare						
outside the home, n (%)						

<sup>149</sup> <sup>a</sup>Participants could select more than one option, so percentages do not sum to 100

150 Note: ILO refers to study participants living in a household with at least one adult working at an

151 industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to

152 participants living nearby these facilities without any known occupational exposure to livestock;

153 Metro refers to participants living in metropolitan areas of North Carolina.

154

155 COVID-19 vaccination over time by study group

10

156 More Metro participants (20.7%) were up to date with COVID-19 vaccines, receiving all doses in the primary series and at least one booster, compared to ILO (13.2%) or ILON (10.3%) 157 158 participants (Table S1). More Metro participants (55.4%) also completed the COVID-19 primary 159 vaccination series, receiving either a first dose and second dose of the Pfizer, Moderna, or 160 Novavax vaccines or a single dose of the Johnson & Johnson vaccine, compared to ILO (51.6%) 161 or ILON (48.4%) participants (Table S1). There was no statistically significant difference in time 162 to primary series completion or becoming up to date between the study groups (p-values for 3-163 group log-rank test 0.4 and 0.1 respectively). However, among participants who received a 164 booster dose, the median date of receiving that booster dose was later for ILO (December 19, 165 2021) compared to ILON (November 3, 2021) and Metro (November 3, 2021) participants, and 166 the same pattern held for primary series completion (Figure 1).





Figure 1. Vaccination over time by study group. Origin is the date of the first FDA Emergency
Use Authorization for a vaccine against COVID-19 (Pfizer-BioNTech), December 11, 2020, and
dotted line is the date on which CDC expanded eligibility for a booster shot to all adults, November
19, 2021 (25).

173	Note: ILO refers to study participants living in a household with at least one adult working at an
174	industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to
175	participants living nearby these facilities without any known occupational exposure to livestock;
176	Metro refers to participants living in metropolitan areas of North Carolina.
177	
178	SARS-CoV-2 IgG antibody and self-reported COVID-19 outcomes
179	Most participant saliva samples tested had SARS-CoV-2 IgG antibodies (Table 2). The
180	prevalence of infection-induced IgG (positive for both N and RBD) was higher among ILO (63%)
181	than among ILON (42.9%) and Metro (48.7%) participants (PR=1.38; 95% CI: 1.06, 1.8). The
182	prevalence of infection- and/or vaccination-induced IgG (positive for RBD) was similar among
183	ILO (78.1%), ILON (63.1%), and Metro participants (77.6%). Significantly more ILO participants
184	reported at least one and at least two COVID-19 symptoms compared to ILON and Metro
185	participants (26). Fewer participants reported thinking they had COVID-19 than had infection-
186	induced IgG. Even fewer participants reported they had ever tested positive for SARS-CoV-2,
407	with the bightest preparties are an Matrix participants (04,40/) followed by U.O.N. (44,00/) and

- 187 with the highest proportion among Metro participants (21.1%), followed by ILON (11.9%) and
- 188 ILO (13.7%) participants.
- 189
- 190 **Table 2.** SARS-CoV-2 antibody assay results and self-reported COVID-19 prevalence and
- 191 prevalence ratios by study group

Outcome		No. pos/total (%)	Crude PR (95% CI)
Antibody assay result	S		
SARS-CoV-2 infecti	on-induced IgG		
(positive for both N and	RBD)		
ILO vs.		46/73 (63)	
	ILON (ref)	36/84 (42.9)	1.47 (1.05, 2.07)

	Metro (ref)	37/76 (48.7)	1.29 (0.95, 1.76)
	ILON and Metro (ref)	73/160 (45.6)	1.38 (1.06, 1.8)
SARS-CoV-2 infectior	- and/or vaccination-		
induced IgG (positive for F	RBD)		
ILO vs.		57/73 (78.1)	
	ILON (ref)	53/84 (63.1)	1.24 (1, 1.53)
	Metro (ref)	59/76 (77.6)	1.01 (0.85, 1.19)
	ILON and Metro (ref)	112/160 (70)	1.12 (0.95, 1.31)
Self-reported COVID-19			
At least one symptom	of COVID-19 <sup>a</sup>		
ILO vs.		48/73 (65.8)	
	ILON (ref)	40/84 (47.6)	1.38 (1.03, 1.85)
	Metro (ref)	39/76 (51.3)	1.28 (0.96, 1.71)
	ILON and Metro (ref)	79/160 (49.4)	1.33 (1.05, 1.7)
At least two symptoms	s of COVID-19 <sup>a</sup>		
ILO vs.		40/73 (54.8)	
	ILON (ref)	29/84 (34.5)	1.59 (1.08, 2.33)
	Metro (ref)	35/76 (46.1)	1.19 (0.85, 1.67)
	ILON and Metro (ref)	64/160 (40)	1.37 (1.02, 1.84)
Ever thought you had	COVID-19		
ILO vs.		19/73 (26)	
	ILON (ref)	16/84 (19)	1.37 (0.76, 2.47)
	Metro (ref)	16/76 (21.1)	1.24 (0.67, 2.28)
	ILON and Metro (ref)	32/160 (20)	1.3 (0.78, 2.17)
Ever tested positive for	r SARS-CoV-2		

13

ILO vs.		10/73 (13.7)	
	ILON (ref)	10/84 (11.9)	0.96 (0.45, 2.02)
	Metro (ref)	16/76 (21.1)	0.67 (0.34, 1.29)
	ILON and Metro (ref)	26/160 (16.2)	0.78 0.42, 1.45)
	Metro (ref) ILON and Metro (ref)	16/76 (21.1) 26/160 (16.2)	0.67 (0.34, 1.29) 0.78 0.42, 1.4

<sup>a</sup>Listed by CDC: fever or chills; cough; shortness of breath or difficulty breathing; lack of energy
or general tired feeling; muscle or body aches; headache; new loss of taste or smell; sore

194 throat, congestion, or runny nose; feeling sick to your stomach or vomiting, diarrhea; abdominal

195 pain; skin rash (26); since February 1, 2020

196 Note: ILO refers to study participants living in a household with at least one adult working at an

197 industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to

198 participants living nearby these facilities without any known occupational exposure to livestock;

199 Metro refers to participants living in metropolitan areas of North Carolina.

200

# 201 SARS-CoV-2 infection-induced IgG prevalence by participant characteristics

202 The proportion of participants with salivary SARS-CoV-2 infection-induced IgG increased 203 over the study period (Table 3). Several participant demographic characteristics and infection 204 prevention behaviors were associated with infection-induced IgG prevalence. The strongest 205 association was for participants who reported generally wearing a mask in public in the past two 206 weeks. Participants who reported not wearing a mask had significantly higher infection-induced 207 IgG prevalence (78.6%) compared to participants who reported wearing a mask (49.3%) 208 (PR=1.59; 95% CI: 1.19, 2.13). Participants with greater than a high school education had 209 significantly lower infection-induced IgG prevalence (38.1%) compared to participants with a 210 high school education or less (60.2%) (PR=0.63, 95% CI:0.48, 0.84). Participants who lived in 211 households with more than one person per bedroom had significantly higher infection-induced 212 IgG prevalence (69.4%) compared to participants in households with one person or fewer per 213 bedroom (46.4%) (PR=1.5, 95% CI:1.15, 1.95). Hispanic/Latino participants had significantly

14

\_

	Characteristic	No. pos./total (%)	PR (95% CI)			
237	confidence intervals (CI) by participant characteristics,	North Carolina, USA,	2021-2022.			
236	Table 3. SARS-CoV-2 infection-induced IgG prevalence	e and prevalence ratio	os (PR) and 95%			
235						
234	the home (0.34) (Figure S1).					
233	and household members per bedroom (0.23), and date	e and level of contact w	vith people outside			
232	value 0.42), followed by date and study group (0.39), g	roup and education le	vel (0.25), group			
231	IgG indicative of infection was between date quartile ar	nd vaccination status (	Cramer's v-test			
230	The highest correlation between factors associa	ated with SARS-CoV-2	2 infection-induced			
229	infection-induced IgG (28).					
228	medical condition listed by CDC as increasing the risk	of getting very sick wit	h COVID-19 had			
227	(PR=1.46, 95% CI: 1.12, 1.89). Almost half (46.6%) of	participants who repor	ted a chronic			
226	infection-induced IgG prevalence (68.3%) compared to	those who did not (46	5.8%) (27)			
225	95% CI: 1.24, 2.03). Participants who reported fever pl	us cough or sore throa	at had higher			
224	prevalence (70.6%) compared with participants who the	ought they had not (44	l.5%) (PR=1.59,			
223	IgG prevalence, participants who thought they had CO	VID-19 had higher infe	ection-induced IgG			
222	least two COVID-19 symptoms listed by the CDC were	not associated with in	fection-induced			
221	positive (45%) (OR 7.58; 95% CI: 2.74, 20.9). While pa	articipants' report of at	least one or at			
220	higher infection-induced IgG prevalence (86.1%) comp	ared to those who rep	orted never testing			
219	CoV-2 IgG. Participants who reported ever testing posi	tive for SARS-CoV-2 h	nad significantly			
218	Participants' COVID-19 symptoms and health h	istory also correspond	led with SARS-			
217	IgG prevalence.					
216	Reduced contact with people outside the home was associated with reduced infection-induced					
215	(PR=1.46; 95% CI: 1.1, 1.94). Only 16.7% of White par	ticipants had infection	-induced IgG.			
214	higher infection-induced IgG prevalence (72.7%) comp	ared to Black participa	ants (49.7%)			

Sampling date, qua	rtiles			
2/23-21-4/30/21	I	14/59 (23.7)	Ref	
4/30/21-9/6/21		23/58 (39.7)	1.67	(0.87, 3.22)
9/6/21-3/11/22		37/58 (63.8)	2.69	(1.49, 4.84)
3/11/22-7/18/22	2	45/58 (77.6)	3.27	(1.85, 5.79)
Sociodemographi	c characteristics			
Age in years, quart	les			
5-27		27/58 (46.6)	Ref	
27-41		28/58 (48.3)	1.04	(0.71, 1.51)
42-55		35/57 (61.4)	1.32	(0.93, 1.86)
55-83		27/57 (47.4)	1.02	(0.68, 1.54)
Sex				
Female		72/139 (51.8)	Ref	
Male		47/94 (50)	0.97	(0.76, 1.23)
Race/ethnicity				
Black		99/199 (49.7)	Ref	
Hispanic/Latino		16/22 (72.7)	1.46	(1.1, 1.94)
White		1/6 (16.7)	0.34	(0.05, 2.14)
Other		3/6 (50)	1.01	(0.45, 2.27)
Education				
<= high school		80/133 (60.2)	Ref	
> high school		37/97 (38.1)	0.63	(0.48, 0.84)
Household member	rs per bedroom			
<= 1 person pe	r bedroom	84/181 (46.4)	Ref	
		I	1	

> 1 person per bedroom	34/49 (69.4)	1.50	(1.15, 1.95)
Work in person outside the home			
No	44/97 (45.4)	Ref	
Yes	75/136 (55.1)	1.22	(0.93, 1.59)
Work in meatpacking			
No	109/257 (42.4)	Ref	
Yes	10/23 (43.5)	0.98	(0.61, 1.57)
Infection prevention behaviors			
Reduced contact with people outside your home			
Yes, all household members	89/178 (50)	Ref	
Yes, some but not all household members	12/17 (70.6)	1.41	(1, 2)
No	13/18 (72.2)	1.44	(1.04, 2)
Avoiding or cancelling travel or vacation plans			
Yes	85/170 (50)	Ref	
No	33/61 (54.1)	1.08	(0.82, 1.43)
Wearing a mask when out in public			
Yes	108/219 (49.3)	Ref	
No	11/14 (78.6)	1.59	(1.19, 2.13)
Washing hands/using hand sanitizer more			
frequently			
Yes	112/221 (50.7)	Ref	
No	6/10 (60)	1.18	(0.7, 1.99)
COVID-19 symptoms and health history			

17

	Ever tested positive for SARS-CoV-2 [OR because			
	log-binomial model failed to converge]			
	No	45/100 (45)	Ref	
	Yes	31/36 (86.1)	7.58	(2.74, 20.9)
	At least one symptom of COVID-19 <sup>a</sup>			
	No	52/106 (49.1)	Ref	
	Yes	67/127 (52.8)	1.08	(0.83, 1.39)
	At least two symptoms of COVID-19 <sup>a</sup>			
	No	62/129 (48.1)	Ref	
	Yes	57/104 (54.8)	1.14	(0.88, 1.47)
	Ever thought you had COVID-19			
	No	77/173 (44.5)		
	Yes	36/51 (70.6)	1.59	(1.24, 2.03)
	Fever with a cough at the same time or fever with a			
	sore throat at the same time <sup>b</sup> (past year)			
	No	89/190 (46.8)	Ref	
	Yes	28/41 (68.3)	1.46	(1.12, 1.89)
	At least one chronic condition associated with			
	severe illness from COVID-19 <sup>c</sup>			
	No	64/162 (39.5)	Ref	
	Yes	55/118 (46.6)	1.25	(0.97, 1.61)
_				

<sup>2</sup>38 <sup>a</sup>Listed by CDC: fever or chills; cough; shortness of breath or difficulty breathing; lack of energy

or general tired feeling; muscle or body aches; headache; new loss of taste or smell; sore

240 throat, congestion, or runny nose; feeling sick to your stomach or vomiting, diarrhea; abdominal

241 pain; skin rash (26); since February 1, 2020

242 <sup>b</sup>CDC definition of influenza-like illness (27)

18

243	<sup>c</sup> Listed by CDC: diabetes, cardiovascular disease, hypertension, immunocompromised
244	condition, autoimmune disease, cancer, chronic kidney disease, asthma, COPD, other chronic
245	lung disease, sickle cell anemia, depression, other mental health disorder (28)
246	
247	SARS-CoV-2 infection-induced IgG prevalence compared to other southern US cohorts
248	The prevalence of SARS-CoV-2 infection-induced IgG was significantly higher in the ILO
249	group of our study population compared to two other southern US cohorts sampled at times
250	overlapping the enrollment and interview dates of our cohort. Infection-induced IgG prevalence
251	was significantly higher in the ILO group of our study population sampled between March 2021
252	and July 2022 (63%) compared to the COVID-19 Prevention in Emory Healthcare Personnel
253	(COPE) Study cohort sampled between January and December 2021 (23.2%) using the same
254	salivary multiplex assay (PR=2.45, 95% CI: 1.80, 3.33) (M. H. Collins and C. D. Heaney,
255	correspondence) (29, 30) (Figure 2). Infection-induced IgG prevalence was also significantly
256	higher in the ILO group of our study population (63%) compared to the MURDOCK Cabarrus
257	County COVID-19 Prevalence and Immunity (C3PI) Study cohort, representative of Cabarrus
258	County, North Carolina, sampled March and monthly June through November 2021, using blood
259	testing with the Abbot Alinity N IgG assay (5.9% to 9.9%; PR range 6.37 to 10.67) (L. K. Newby
260	and D. Wixted, correspondence) (31).

19



*Figure 2.* SARS-CoV-2 infection-induced IgG prevalence ratios (PRs) among ILO household
group participants (during Apr 2021-Jul 2022) in this study compared to other southern US
reference populations.

Note: ILO refers to study participants living in a household with at least one adult working at an
industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to
participants living nearby these facilities without any known occupational exposure to livestock;
Metro refers to participants living in metropolitan areas of North Carolina; Cabarrus refers to
C3PI Cabarrus County, NC general population-representative cohort; Atlanta HCW refers to
Emory COPE health care worker cohort.

272

262

#### 273 DISCUSSION

We measured salivary SARS-CoV-2 IgG prevalence among 279 participants, 94% of whom were Black or Hispanic/Latino, underrepresented groups in SARS-CoV-2 seroprevalence surveys. To our knowledge, this study presents the first estimates of SARS-CoV-2 infectioninduced antibody prevalence among industrial livestock operation (ILO) workers and their household members, which we observed to be high (63%) compared to participants with no household members working at industrial livestock operation (45.6%) (Table 2). This is

20

280 consistent with research connecting the agricultural sector and meatpacking facilities with 281 COVID-19 transmission among workers, and connecting meatpacking facilities with 282 transmission in nearby communities (10, 12, 13, 32). However, neither work at a meatpacking 283 facility nor work in person outside the home were associated with elevated prevalence of SARS-284 CoV-2 infection-induced IgG in our study population (Table 3), and participants living in areas of 285 high industrial livestock operation intensity did not have a higher prevalence (42.9%) compared 286 to metropolitan-area participants (48.7%) (Table 2). This may be due to the relatively small 287 number of meatpacking workers (n=23) and relatively large number of participants with other 288 high-COVID-19-risk jobs and factors (e.g., low income and communities of color). Another 289 contributing factor could be case rate convergence over time between high intensity livestock 290 operation areas and metro areas. As the prevalence of COVID-19 increased in summer and fall 291 2020, the importance of any single transmission route decreased; also, if many meatpacking 292 workers and nearby residents were infected earlier on, those communities might have a greater 293 rate of at least temporary immunity (32). Our group definitions of ILO, ILON, and Metro also 294 collapse many differences that have been connected to exposure to SARS-CoV-2 and COVID-295 19: time, age, sex, race/ethnicity, education, and urbanicity, among others (14–16). 296 Self-reported symptoms of COVID-19 were also higher in the ILO compared to 297 combined ILO and Metro groups (Table 2). This could be because of more COVID-19 cases, 298 though some contribution could also be from other health effects related to industrial livestock 299 production and processing work. Hog and poultry production work have been associated with 300 respiratory and infectious disease broadly, and processing work has also been associated with 301 respiratory, infectious, and skin disease, which overlap with almost all COVID symptoms listed 302 by CDC (6, 26, 33, 34). While 51% of participants overall had SARS-CoV-2 infection-induced 303 IgG, less than half reported thinking they had COVID-19, and only 15.4% reported ever testing

304 positive for COVID-19 (Table 2). Of participants who tested positive for infection-induced IgG,

305 68% did not think they had COVID-19 (Table 3). This is a higher proportion compared to the

21

306 estimated prevalence of asymptomatic infections among people with confirmed COVID-19, 40-307 45% (35). Participants might have attributed any symptoms to other health issues, including 308 some related to ILO work or residence near ILOs. The lower percentage of people ever testing 309 positive for COVID-19 even compared to the low percentage of people who thought they had 310 COVID also underlines the importance of accessible COVID-19 testing. 311 A higher proportion of Metro compared to ILO or ILON participants completed the 312 primary vaccination series and received at least one booster, although the difference between 313 groups was not statistically significant, and the groups had similar SARS-CoV-2 infection-314 and/or vaccination-induced IgG (positive for RBD) (Figure 1, Table 2). Among participants who 315 completed the primary vaccination series, the median date of completion was later for ILO 316 compared to ILON and Metro participants, and the same pattern held for booster doses (Figure 317 1). Although the differences in vaccination timing between groups were not statistically 318 significant, these delays are notable because of the spread of the more-contagious Delta and 319 Omicron variants in summer and winter 2021, respectively (36). Because a greater proportion of 320 ILO participants had a high school education or less, our results are also consistent with 321 evidence of vaccination disparities by social class, and with evidence that vaccination coverage 322 increased most during spring and summer 2021 among people with lower education and 323 income (37).

324 COVID-19 vaccination rates in our study population were lower than the US and North 325 Carolina general populations. The proportion of our study population (ILO, ILON, and Metro 326 combined) who completed the initial vaccination protocol (52%) was lower than the proportion of 327 North Carolina (62.9%) and US residents (67.2%) vaccinated at the last date of follow-up, July 328 18, 2022 (38) (Table S1). However, participants may have become vaccinated after their initial 329 or follow-up call; the proportion of participants who had completed the initial vaccination protocol 330 by the median initial or follow-up call date was 50.7%, closer to the proportion of North Carolina 331 (57.3%) and the US (62.6%) at that date, January 10, 2022. The proportion of our cohort who

received at least one booster dose was also lower compared to North Carolina and the US at

332

22

333 the end of the study, but similar at the median follow-up date (38). Although our modest sample 334 size and timing of initial and follow-up call complicate comparison to North Carolina and the US, 335 our results support the importance of dismantling vaccination barriers, especially for ILO 336 workers, their household members, and rural communities. 337 The proportion of participants with SARS-CoV-2 infection-induced IgG prevalence 338 increased over the course of the study (Table 3). This is consistent with the spread of the virus 339 over time and trends in other seroprevalence surveys (24, 39). Among health behaviors 340 assessed, wearing a mask had the highest protective effect (Table 3). This is consistent with 341 cohort, ecological, and modelling studies on the efficacy of masks for COVID-19 protection (40). 342 Reporting mask use could also be an indicator of other modifiable and non-modifiable risk 343 factors. We did not ask about the frequency of mask use overall, mask use in particular contexts 344 that might be higher risk transmission settings, or about the type(s) of masks participants used. 345 all of which affect any relationship between mask use and SARS-CoV-2 exposure. 346 Education level and ethnicity were also associated with SARS-CoV-2 infection-induced 347 IgG. A study of the joint effects of socioeconomic position estimated by education level, 348 race/ethnicity, and gender on COVID-19 mortality among working-age adults found the same 349 trends of higher COVID-19 mortality for low vs. high socioeconomic position adults and for Black 350 and Hispanic/Latino vs. White adults (41). Our results are also consistent with elevated rates of 351 infection-induced seroprevalence among Hispanic/Latino and Black compared with White blood 352 donors across the US (24) and elevated infection-induced seroprevalence among 353 Hispanic/Latino and Black North Carolina residents in surveillance based on hospital remnant 354 blood samples (16), as well as with disproportionate numbers of cases and deaths among 355 Hispanic/Latino, Native American, and Black communities (14). People with fewer 356 socioeconomic resources are less able to use different strategies to avoid exposure to SARS-357 CoV-2 and more likely to work in crowded occupations or occupations with contact with the

23

public (42). Under racialized capitalism, Hispanic/Latino, Indigenous, and Black workers face
occupational status disadvantages even within specific jobs (42, 43).

360 We found that participants with more than one person per household bedroom had 361 higher prevalence of SARS-CoV-2 infection-induced IgG (Table 3). Living in more crowded 362 conditions could increase exposures to SARS-CoV-2 from household members. Level of 363 contact with people outside of the home was also associated with higher infection-induced IgG 364 prevalence (Table 3). A systematic review of observational studies of SARS-CoV-2 and the 365 betacoronaviruses that cause severe acute respiratory syndrome (SARS-CoV-1) and Middle 366 east respiratory syndrome (MERS) found reduced transmission of viruses with physical 367 distancing of 1m or more as well as with face mask usage, consistent with our results (44). 368 Participants' COVID-19 health history and symptoms also corresponded with SARS-369 CoV-2 IgG prevalence. Close to 90% of participants who reported ever testing positive for 370 SARS-CoV-2 had infection-induced IgG (positive for both N and RBD), compared to 45% of 371 participants who did not report ever testing positive (Table 3). Nucleocapsid (N) IgG is useful for 372 determining response to infection because these antibodies are produced in the immune 373 response to infection and not in the response to vaccines currently approved for use in the US 374 (23). However, a limitation is that N IgG half-life in the body is generally shorter compared to 375 RBD and S IgG (45). Participants who reported testing positive for SARS-CoV-2 but tested 376 negative for N IgG could have been infected longer ago and have levels of N IgG below the 377 positivity cutoff. Participants who reported thinking they had COVID-19 and participants who 378 reported influenza-like illness had a higher prevalence of infection-induced IgG compared to 379 participants who did not, although there was a similar prevalence of infection-induced IgG 380 among participants who reported at least one or at least two symptoms of COVID-19 compared 381 to those who did not (Table 3). This is consistent with relatively high proportions of 382 asymptomatic infections (35), overlap between COVID-19 and other health condition symptoms, 383 and limited durability of N IgG response.

24

384 We found prevalence of SARS-CoV-2 infection-induced IgG higher than in comparable 385 cohorts. Infection-induced IgG prevalence in the ILO group of our study population was more 386 than twice that in Emory University's COPE cohort of Atlanta healthcare workers sampled from 387 January to December 2021 using the same salivary multiplex assay (M. H. Collins and C. D. 388 Heaney, correspondence) (29, 30) (Figure 2). Healthcare workers are at higher risk for COVID-389 19 compared to the general population (46, 47). High infection-induced IgG among ILO 390 participants compared to workers in another high-COVID-19-risk occupation sampled with the 391 same assay during an overlapping time period underlines the high exposures among North 392 Carolina livestock operation workers and their household members. Infection-induced IgG 393 prevalence among ILO participants was more than five times the highest prevalence observed 394 in March and monthly June through November 2021 in Duke University's Cabarrus County, 395 North Carolina general-population-representative cohort (L. K. Newby and D. Wixted, 396 correspondence) (31) (Figure 2). Infection-induced IgG prevalence was also higher in the ILO 397 group of our study population (63%) compared to nationwide serology estimates. A study of 398 blood donations estimated infection-induced seroprevalence to be 28.8% overall in December 399 2021; higher among Hispanic (40.2%) and Black (32.5%) donors and donors living in the South 400 (33.5%) during the same time period (24). Infection-induced IgG prevalence in our cohort was 401 also generally higher compared to estimates using residual data from commercial labs across 402 the US weighted by age, sex, and metropolitan status, which ranged from 20.8% to 57.7% 403 nationally and 22.5% to 52% in North Carolina during the sixteen sampling periods that 404 overlapped our study period (36, 39) (Figure S2). 405 An important consideration for interpreting our results is our non-population-406 representative snowball sampling strategy. Participants were volunteers recruited primarily from 407 social networks of community organizers with our partner community organization and might 408 differ in several ways from the eastern North Carolina population in general. Another 409 consideration is our enrollment period from February 2021 to July 2022, including changing

25

410 recommendations on vaccination and boosters, as well as increasing cases due to the more 411 contagious Delta and Omicron variants. Vaccination, exposure, and treatment options varied for 412 participants over the course of enrollment and differences over time may obscure differences by 413 study group or participant characteristics. The long enrollment period also complicates 414 comparisons with other southern US cohorts and CDC nationwide studies (Figure S2). Our 415 study also has limitations associated with antibody test characteristics. Our multiplex assay was 416 optimized for specificity over sensitivity, so we may have missed a proportion of infection-417 induced and vaccination or infection-induced antibody responses among our participants, 418 especially for those infected a longer time ago who may have sero-reverted. The half-life of 419 SARS-CoV-2 N IgG using our assay was about 64 days, compared to RBD about 100 days 420 (45). Because we sampled participants through July 18, 2022, 910 days after the first confirmed 421 case in the US, we likely underestimated infection-induced SARS-CoV-2 exposure. 422 Our findings show high rates of SARS-CoV-2 infection-induced IgG in a predominantly 423 rural, Black, and Hispanic/Latino North Carolina cohort, especially among industrial livestock 424 operation workers and their families. We add to reports of high numbers of cases associated 425 with meatpacking facilities early in the course of the pandemic and to evidence of health 426 disparities in exposure to SARS-CoV-2 by socioeconomic position. Delays in the timing of 427 receipt of COVID-19 vaccination reinforce the importance of dismantling vaccination barriers. 428 especially for industrial livestock operation workers and their household members. Associations 429 between masking and physical distancing with antibody results also add to evidence of the 430 effectiveness of these prevention strategies.

431

# 432 MATERIALS AND METHODS

433 Study design and participants

This study was designed and conducted in partnership with REACH. Data were
collected by REACH community organizers and researchers from Johns Hopkins Bloomberg

26

School of Public Health (JHSPH). Using a snowball sampling approach, REACH community organizers recruited ILO, ILON, and metro-area households. All enrolled households had at least one adult (≥18 years old) enrolled into the study. In addition to the one adult, all additional household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included ability to understand spoken English or Spanish and access to household phone or mobile device and refrigerator. The study was developed in collaboration between JHSPH and REACH. The JHSPH Institutional Review Board (IRB) approved this study (IRB00014420).

443

### 444 Questionnaire data and saliva sample collection

445 Before participation, adult participants provided oral consent. For children 0-6 years old, 446 a parent or legal guardian provided permission, oral assent, and guestionnaire responses for 447 the child. For children 7-17 years old, a parent/legal guardian provided permission for the child 448 and the child provided oral assent and questionnaire responses, with parents answering some 449 questions as appropriate (e.g., health history). Recruitment, consent, questionnaires, and saliva 450 self-collection were conducted remotely via video or phone call, without physical contact 451 between study team and participants. Questionnaire responses were recorded and training and 452 supervision of biospecimen self-collection were provided during the same video or phone call. 453 Participants and parents or legal guardians of children 0-6 reported demographic information; 454 work, school, or childcare outside the home; infection prevention behaviors; and health history, 455 including information related to COVID-19 vaccination and symptoms consistent with COVID-456 19. Participants who worked at an ILO were also asked more detailed questions about livestock 457 production and processing activities. Study questionnaires were developed in collaboration with 458 REACH organizers. REACH interviewers included those fluent in English and Spanish, and 459 participants had the ability to respond in either language. REACH and JHSPH interviewers 460 recorded participant responses in REDCap, a secure web application for managing online 461 surveys (48, 49).

27

462 After consent, all enrolled households received a study package containing all materials for saliva self-collection, self-collection procedure information, and packaging materials via 463 464 REACH drop-off or direct shipping. During the questionnaire, training, and sampling call, 465 REACH or JHSPH interviewers instructed all enrolled participants on how to collect saliva 466 samples and stayed on the call as participants collected samples to answer any questions and 467 ascertain if participants followed procedures. All participants provided two self-collected saliva 468 samples: an oral fluid saliva sample and a passive drool saliva sample. For the oral fluid 469 sample, participants brushed the Oracol+ 2.0 saliva collection device (Malvern Medical 470 Developments, Worcester, United Kingdom) along their gums for 1-2 minutes. Participants were 471 instructed to store their samples in a refrigerator until pickup by a REACH courier or direct 472 shipping to JHSPH. Because booster vaccination was recommended by the CDC during the 473 course of our study, we added questions about this topic mid-study and recontacted participants 474 not initially asked.

475

## 476 Multiplex SARS-CoV-2 IgG assay for oral fluid

477 Oral fluid samples were separated from sponges by centrifugation and tested for SARS-478 CoV-2 nucleocapsid (N), receptor-binding domain (RBD), and spike (S) IgG, using a multiplex 479 bead-based immunoassay based on Luminex technology, which has been described previously 480 (N. Pisanic, A. Antar, K. Kruczynski, M. G. Rivera, K. Spicer, P. R. Randad, A. Pekosz, S. L. 481 Klein, M. J. Betenbaugh, B. Detrick, W. Clarke, D. L. Thomas, Y. C. Manabe, and C. D. Heaney, 482 submitted for publication) (19, 20). Briefly, the multiplex assay included SARS-CoV-2 N, RBD, 483 and S antigens coupled to magnetic microparticles, and a background control bead coated with 484 bovine serum albumin (BSA). Saliva samples were centrifuged for 5 min at 10,000 g and 10 µL 485 supernatant were added to a 96-well assay plate containing 40 µL bead mix (1,000 beads per 486 bead set) in assay buffer (PBS-TBN). After incubation to allow for binding of SARS-CoV-2 487 specific IgG present in saliva samples, beads were washed, and fluorophore-labeled anti-

28

488 human IgG was added to the plate. After a second incubation to allow for binding of labeled
489 anti-IgG to salivary IgG on the beads, the plate was washed again, and median fluorescent
490 intensity (MFI) was read on a Luminex MagPix instrument.

491 To determine optimum performance cutoffs for infection-induced IgG, we used 1320 492 saliva samples from individuals without known prior exposure to the SARS-CoV-2 virus or 493 vaccine (presumed negatives) and 325 saliva samples collected >14 days after symptom onset 494 of a molecularly confirmed SARS-CoV-2 infection (infection-induced positives). To determine 495 optimum performance cutoffs for infection- and/or vaccination-induced IgG, we used 1002 saliva 496 samples from individuals without known prior exposure to the SARS-CoV-2 virus or vaccine 497 (presumed negatives) and 492 saliva samples collected >14 days after symptom onset of a 498 molecularly confirmed SARS-CoV-2 infection and/or >14 days after completing the primary 499 COVID-19 vaccination series (infection- and/or vaccination-induced positives). We first 500 subtracted the BSA signal from all SARS-CoV-2 signals. The best algorithm for infection-501 induced IgG relied on N (Cat. No. Z03480, Genscript, NJ, USA) and RBD (Cat. No. 40592-502 V08H, Sino Biological, Beijing, China) (sensitivity=97.6%, specificity=99.4%) and the best 503 algorithm for infection- and/or vaccination-induced IgG response relied on RBD (Cat. No. 504 40592-V08H, Sino Biological, Beijing, China) (sensitivity=99.4%, specificity=99.3%).

505

# 506 Data from other southern US cohorts

507 Seropositivity data from the COVID-19 Prevention in Emory Healthcare Personnel 508 (COPE) Study cohort were obtained through correspondence (M. H. Collins and C. D. Heaney, 509 correspondence). Participants were health care providers recruited from 4 university-affiliated 510 hospitals and clinics in Atlanta, Georgia, and saliva samples for serology were collected at 511 enrollment, at 3 months, and at 6 months. Oral fluid saliva samples were tested with the 512 multiplex assay described above, as in our North Carolina study population (19, 20, 29, 30). 513 Monthly seropositivity and N seropositivity data from the Cabarrus County COVID-19

29

514	Prevalence and Immunity (C3PI) were also obtained through correspondence (L. K. Newby and
515	D. Wixted, correspondence). Participants were selected from a larger ongoing cohort study
516	through a weighted, randomized scheme to approximate the sex, age, and race/ethnicity of
517	Cabarrus County, North Carolina. Blood samples for serology were collected monthly, and
518	serology testing was performed with the Abbott Alinity IgG N protein antibody assay (specificity
519	99.9% and sensitivity 100%) (31). Nationwide and North Carolina infection-induced antibody
520	seroprevalence estimates from CDC commercial laboratory surveys were downloaded from
521	https://covid.cdc.gov/covid-data-tracker/#national-lab (36).

522

#### 523 Statistical analysis

524 We first compared the distribution of demographic characteristics and potential risk 525 factors for SARS-CoV-2 IgG among the ILO household, ILON household, and metropolitan area 526 (Metro) household groups. Using participants' reported dates of receiving a first dose, receiving 527 a second dose (or first dose for the Janssen [Johnson & Johnson]), and receiving a booster 528 dose of the COVID-19 vaccine, we plotted time to each vaccination event by group and tested 529 for difference in time to each vaccination event by group using the 3-group log-rank test 530 implemented in survdiff function (survival package) in R. Next, we calculated the crude 531 prevalence of salivary SARS-CoV-2 IgG outcomes in each household group (ILO, ILON, and 532 Metro), and the crude prevalence of infection-induced IgG across levels of participant 533 characteristics. For SARS-CoV-2 IgG and self-reported COVID-19 outcomes, we used 534 generalized estimating equation (GEE) log-binomial regression models clustered by household 535 to calculate crude prevalence ratios (PRs) and 95% confidence intervals (CIs) comparing 536 outcome prevalence among the ILO versus the ILON, Metro, and combined ILON and Metro 537 groups. We also used GEE log-binomial regression models to calculate crude prevalence ratios 538 of infection-induced IgG by participant characteristics, with the category with the greatest 539 number of participants as the reference group. To compare infection-induced IgG prevalence in

30

540 our c	ohort to other southe	n US cohorts, v	we used log-binomial	regression models to calculate
-----------	-----------------------	-----------------	----------------------	--------------------------------

- 541 crude prevalence ratios between the ILO group versus the ILON, Metro, and other southern US
- 542 cohort groups with enrollment dates overlapping at least one day of our enrollment date range.
- 543 All statistical analyses were completed in R 2022.02.0 (50).
- 544

# 545 **REFERENCES**

- 546 1. USDA. 2022. Annual Statistical Bulletin. USDA National Agricultural Statistics Service,
- 547 North Carolina Field Office.
- 548 https://www.nass.usda.gov/Statistics\_by\_State/North\_Carolina/Publications/Annual\_Statist
- 549 ical\_Bulletin/index.php. Retrieved 12 April 2022.
- Azaroff LS, Levenstein C, Wegman DH. 2002. Occupational injury and illness surveillance:
   conceptual filters explain underreporting. Am J Public Health 92:1421–1429.
- Leigh JP, Du J, McCurdy SA. 2014. An estimate of the U.S. government's undercount of
   nonfatal occupational injuries and illnesses in agriculture. Annals of Epidemiology 24:254–
   259.
- 555 4. Ceryes CA, Heaney CD. 2019. "Ag-gag" laws: evolution, resurgence, and public health
  556 implications. New Solutions: A Journal of Environmental and Occupational Health Policy
  557 28:664–682.
- 558 5. BLS. Incidence rates of nonfatal occupational injuries and illnesses by industry and case 559 types, 2020. US Bureau of Labor Statistics: Injuries, Illnesses, and Fatalities.
- 560 https://www.bls.gov/iif/oshwc/osh/os/summ1\_00\_2020.htm. Retrieved 5 October 2022.
- 561 6. Donham KJ. 2010. Community and occupational health concerns in pork production: a
  562 review. Journal of Animal Science 88:E102–E111.

31

563	7.	Wing S, Wolf S. 2000. Intensive livestock operations, health, and quality of life among
564		eastern North Carolina residents. Environmental Health Perspectives 108:6.

Solution Section 2000. Concentrated swine feeding operations and public health: a
review of occupational and community health effects. Environ Health Perspect 108:685–
699.

568 9. Dyal JW, Grant MP, Broadwater K, Bjork A, Waltenburg MA, Gibbins JD, Hale C, Silver M,

569 Fischer M, Steinberg J, Basler CA, Jacobs JR, Kennedy ED, Tomasi S, Trout D, Hornsby-

570 Myers J, Oussayef NL, Delaney LJ, Patel K, Shetty V, Kline KE, Schroeder B, Herlihy RK,

571 House J, Jervis R, Clayton JL, Ortbahn D, Austin C, Berl E, Moore Z, Buss BF, Stover D,

572 Westergaard R, Pray I, DeBolt M, Person A, Gabel J, Kittle TS, Hendren P, Rhea C,

573 Holsinger C, Dunn J, Turabelidze G, Ahmed FS, deFijter S, Pedati CS, Rattay K, Smith

574 EE, Luna-Pinto C, Cooley LA, Saydah S, Preacely ND, Maddox RA, Lundeen E, Goodwin

575 B, Karpathy SE, Griffing S, Jenkins MM, Lowry G, Schwarz RD, Yoder J, Peacock G,

576 Walke HT, Rose DA, Honein MA. 2020. COVID-19 among workers in meat and poultry

577 processing facilities — 19 states, April 2020. MMWR Morb Mortal Wkly Rep 69.

578 10. Waltenburg MA, Victoroff T, Rose CE, Butterfield M, Jervis R, Fedak K, Gabel JA,

579 Feldpausch A, Dunne EM, Austen C, Ahmed FS, Tubach S, Rhea C, Krueger A, Crum DA,

580 Vostok J, Moore MJ, Turabelidze G, Stover D, Donahue M, Edge K, Gutierrez B, Kline KE,

581 Martz N, Cummins J, Barbeau B, Murphy J, Darby B, Graff NR, Dostal TKH, Pray IW,

582 Tillman C, Dittrich MM, Burns-Grant G, Lee S, Spieckerman A, Iqbal K, Griffing SM,

Lawson A, Mainzer HM, Bealle AE, Edding E, Arnold KE, Rodriguez T, Merkle S, Pettrone

584 K, Schlanger K, LaBar K, Hendricks K, Lasry A, Krishnasamy V, Walke HT, Rose DA,

585 Honein MA, COVID-19 Response Team. 2020. Update: COVID-19 among workers in meat

586	and poultry processing facilities — United States, April–May 2020. MMWR Morb Mortal
587	Wkly Rep 69:887–892.

- 588 11. 2021. House Select Subcommittee on the Coronavirus Crisis: How The Meatpacking
- 589 Industry Failed the Workers Who Feed America. Staff Memorandum. Washington, DC.
- 590 https://coronavirus.house.gov/sites/democrats.coronavirus.house.gov/files/2021.10.27%20
- 591 Meatpacking%20Report.Final\_.pdf.
- Taylor CA, Boulos C, Almond D. 2020. Livestock plants and COVID-19 transmission. Proc
  Natl Acad Sci U S A 117:31706–31715.
- 13. Waltenburg MA, Rose CE, Victoroff T, Butterfield M, Dillaha JA, Heinzerling A, Chuey M,
- 595 Fierro M, Jervis RH, Fedak KM, Leapley A, Gabel JA, Feldpausch A, Dunne EM, Austin C,
- 596 Pedati CS, Ahmed FS, Tubach S, Rhea C, Tonzel J, Krueger A, Crum DA, Vostok J,
- 597 Moore MJ, Kempher H, Scheftel J, Turabelidze G, Stover D, Donahue M, Thomas D, Edge
- 598 K, Gutierrez B, Berl E, McLafferty M, Kline KE, Martz N, Rajotte JC, Julian E, Diedhiou A,
- 599 Radcliffe R, Clayton JL, Ortbahn D, Cummins J, Barbeau B, Carpenter S, Pringle JC,
- 600 Murphy J, Darby B, Graff NR, Dostal TKH, Pray IW, Tillman C, Rose DA, Honein MA.
- 601 2021. Coronavirus Disease among Workers in Food Processing, Food Manufacturing, and
- 602 Agriculture Workplaces. Emerging Infectious Diseases 27:243–249.
- Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. 2021. The Disproportionate Impact of
  COVID-19 on Racial and Ethnic Minorities in the United States. Clinical Infectious
  Diseases 72:703–706.
- 5. Zalla LC, Martin CL, Edwards JK, Gartner DR, Noppert GA. 2021. A Geography of Risk:
   Structural Racism and COVID-19 Mortality in the United States. American Journal of
- 608 Epidemiology 190:1439–1446.

609	16.	Lopez CA, Cur	nningham C	H, Pugh S,	Brandt K,	Vanna UP,	Delacruz MJ,	Guerra Q,
-----	-----	---------------	------------	------------	-----------	-----------	--------------	-----------

- 610 Bhowmik DR, Goldstein SJ, Hou YJ, Gearhart M, Wiethorn C, Pope C, Amditis C, Pruitt K,
- 611 Newberry-Dillon C, Schmitz JL, Premkumar L, Adimora AA, Baric RS, Emch M, Boyce RM,
- Aiello AE, Fosdick BK, Larremore DB, de Silva AM, Juliano JJ, Markmann AJ. 2022.
- 613 Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in
- 614 Central North Carolina from April to December 2020. mSphere 7:e0084121.
- 615 17. CDC. 2020. Cases, Data, and Surveillance. Centers for Disease Control and Prevention.
- 616 https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-
- 617 discovery/hospitalization-death-by-race-ethnicity.html. Retrieved 11 March 2021.
- 618 18. Sherman AC, Smith T, Zhu Y, Taibl K, Howard-Anderson J, Landay T, Pisanic N,
- 619 Kleinhenz J, Simon TW, Espinoza D, Edupuganti N, Hammond S, Rouphael N, Shen H,
- 620 Fairley JK, Edupuganti S, Cardona-Ospina JA, Rodriguez-Morales AJ, Premkumar L,
- 621 Wrammert J, Tarleton R, Fridkin S, Heaney CD, Scherer EM, Collins MH. 2021.
- 622 Application of SARS-CoV-2 Serology to Address Public Health Priorities. Front Public
- 623 Health 9:744535.
- 19. Heaney CD, Pisanic N, Randad PR, Kruczynski K, Zhu X, Littlefield K, Patel EU, Shrestha
- 625 R, Shoham S, Sullivan D, Gebo K, Hanley D, Quinn TC, Casadevall A, Zenilman JM,
- 626 Pekosz A, Bloch EM, Tobian AAR. Comparative performance of multiplex salivary and
- 627 commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization628 titers 25.
- 20. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, Klein SL,
  Betenbaugh MJ, Clarke WA, Laeyendecker O, Caturegli PP, Larman HB, Detrick B, Fairley
  JK, Sherman AC, Rouphael N, Edupuganti S, Granger DA, Granger SW, Collins MH,

34

632	Heaney CD.	2020. COVIE	-19 Serology	at Population	Scale: SARS	-CoV-2-Specific

- 633 Antibody Responses in Saliva. J Clin Microbiol 59.
- 634 21. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, Raeber ME,
- 635 Adamo S, Weigang S, Emmenegger M, Hasler S, Bosshard PP, De Cecco E, Bächli E,
- 636 Rudiger A, Stüssi-Helbling M, Huber LC, Zinkernagel AS, Schaer DJ, Aguzzi A, Kochs G,
- 637 Held U, Probst-Müller E, Rampini SK, Boyman O. 2021. Systemic and mucosal antibody
- 638 responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin
- 639 Immunol 147:545-557.e9.

Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. 2020. Mucosal Immunity in COVID-19:
A Neglected but Critical Aspect of SARS-CoV-2 Infection. Frontiers in Immunology
11:3221.

- 643 23. Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, Yan T, Cao C, Gurry C,
- Hankins CA, Cheng MP, Gingras A-C, Mazer BD, Papenburg J, Langlois M-A. 2022.
- Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. Open Forum Infectious Diseases9:ofab632.
- 647 24. Jones JM, Opsomer JD, Stone M, Benoit T, Ferg RA, Stramer SL, Busch MP. 2022.
- 648 Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates
- Based on Blood Donations, July 2020-December 2021. JAMA 328:298–301.
- 650 25. CDC. 2022. CDC Museum COVID-19 Timeline. Centers for Disease Control and
- 651 Prevention. https://www.cdc.gov/museum/timeline/covid19.html. Retrieved 1 September652 2022.

653 26	CDC.	2022.	Coronavirus	Disease 2	2019 (	COVID-19	) – S'	ymptoms.	Centers	for D	Jisease
--------	------	-------	-------------	-----------	--------	----------	--------	----------	---------	-------	---------

- 654 Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-
- 655 testing/symptoms.html. Retrieved 10 August 2022.
- 656 27. CDC. 2022. Weekly U.S. Influenza Surveillance Report. Centers for Disease Control and
- 657 Prevention. https://www.cdc.gov/flu/weekly/index.htm. Retrieved 12 August 2022.
- 658 28. CDC. 2022. People with Certain Medical Conditions. Centers for Disease Control and
- 659 Prevention. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-
- 660 with-medical-conditions.html. Retrieved 12 August 2022.
- 661 29. Howard-Anderson JR, Adams C, Dube WC, Smith TC, Sherman AC, Edupuganti N,
- 662 Mendez M, Chea N, Magill SS, Espinoza DO, Zhu Y, Phadke VK, Edupuganti S, Steinberg
- 563 JP, Lopman BA, Jacob JT, Fridkin SK, Collins MH. 2022. Occupational risk factors for
- severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare
- 665 personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory
- Healthcare Personnel (COPE) Study. Infect Control Hosp Epidemiol Online ahead ofprint:1–8.
- 668 30. Howard-Anderson JR, Adams C, Sherman AC, Dube WC, Smith TC, Edupuganti N, Chea
- 669 N, Magill SS, Espinoza DO, Zhu Y, Phadke VK, Edupuganti S, Steinberg JP, Lopman BA,
- 670 Jacob JT, Collins MH, Fridkin SK. 2022. Occupational risk factors for severe acute
- 671 respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A
- 672 cross-sectional analysis of subjects enrolled in the COVID-19 Prevention in Emory
- 673 Healthcare Personnel (COPE) study. Infect Control Hosp Epidemiol 43:381–386.
- 874 31. Neighbors CE, Wu AE, Wixted DG, Heidenfelder BL, Kingsbury CA, Register HM, Louzao
  875 R, Sloane R, Eckstrand J, Pieper CC, Faldowski RA, Denny TN, Woods CW, Newby LK.

- 676 2022. The Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study: design,
- 677 methods, and baseline characteristics. Am J Transl Res 14:5693–5711.
- 678 32. Saitone TL, Aleks Schaefer K, Scheitrum DP. 2021. COVID-19 morbidity and mortality in
- U.S. meatpacking counties. Food Policy 101:102072.
- 680 33. Mitloehner FM, Calvo MS. 2008. Worker health and safety in concentrated animal feeding
  681 operations. J Agric Saf Health 14:163–187.
- 682 34. Campbell DS. 1999. Health hazards in the meatpacking industry. Occup Med 14:351–372.
- 683 35. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, Wu Y, Liu M. 2021. Global Percentage of
- 684 Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With
- 685 Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Network
  686 Open 4:e2137257.
- 687 36. CDC. 2020. COVID Data Tracker. Centers for Disease Control and Prevention.
- 688 https://covid.cdc.gov/covid-data-tracker. Retrieved 7 June 2021.
- 689 37. Nguyen KH, Nguyen K, Geddes M, Allen JD, Corlin L. 2022. Trends in COVID-19
- 690 vaccination receipt and intention to vaccinate, United States, April to August, 2021.
- 691 American Journal of Infection Control 50:699–703.
- 692 38. State-by-state data on COVID-19 vaccinations in the United States. Our World in Data.
- 693 https://ourworldindata.org/us-states-vaccinations. Retrieved 23 August 2022.
- 39. Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, Lee A, Moyse D, Havers FP,
- Harding L, Fry AM, Hall AJ, Martin K, Biel M, Deng Y, Meyer WA, Mathur M, Kyle T,
- 696 Gundlapalli AV, Thornburg NJ, Petersen LR, Edens C. 2021. Estimated SARS-CoV-2
- 697 Seroprevalence in the US as of September 2020. JAMA Intern Med 181:450–460.

698	40.	Howard J, Hu	Jang A, Li Z	, Tufekci Z,	Zdimal V,	van der	Westhuizen	H-M, von	Delft A,	Price
-----	-----	--------------	--------------	--------------	-----------	---------	------------	----------	----------	-------

- A, Fridman L, Tang L-H, Tang V, Watson GL, Bax CE, Shaikh R, Questier F, Hernandez
- D, Chu LF, Ramirez CM, Rimoin AW. 2021. An evidence review of face masks against
- 701 COVID-19. Proceedings of the National Academy of Sciences 118:e2014564118.
- 41. Pathak EB, Menard J, Garcia RB, Salemi JL. 2021. Social Class, Race/Ethnicity, and
- 703 COVID-19 Mortality Among Working Age Adults in the United States.
- 42. Pathak EB, Menard JM, Garcia RB, Salemi JL. 2022. Joint Effects of Socioeconomic
- 705 Position, Race/Ethnicity, and Gender on COVID-19 Mortality among Working-Age Adults in
- the United States. Int J Environ Res Public Health 19:5479.
- 707 43. Paul A. Landsbergis, Joseph G. Grzywacz, Anthony D. LaMontagne. 2014. Work
  708 organization, job insecurity, and occupational health disparities. American Journal of
  709 Industrial Medicine 57:495–515.
- 710 44. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, Chu DK, Akl EA, El-
- harakeh A, Bognanni A, Lotfi T, Loeb M, Hajizadeh A, Bak A, Izcovich A, Cuello-Garcia
- 712 CA, Chen C, Harris DJ, Borowiack E, Chamseddine F, Schünemann F, Morgano GP,
- 713 Schünemann GEUM, Chen G, Zhao H, Neumann I, Chan J, Khabsa J, Hneiny L, Harrison
- L, Smith M, Rizk N, Rossi PG, AbiHanna P, El-khoury R, Stalteri R, Baldeh T, Piggott T,
- 715 Zhang Y, Saad Z, Khamis A, Reinap M, Duda S, Solo K, Yaacoub S, Schünemann HJ.
- 716 2020. Physical distancing, face masks, and eye protection to prevent person-to-person
- 717 transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. The
- 718 Lancet 395:1973–1987.
- 45. Randad PR, Pisanic N, Kruczynski K, Howard T, Rivera MG, Spicer K, Antar AAR, Penson
- 720 T, Thomas DL, Pekosz A, Ndahiro N, Aliyu L, Betenbaugh MJ, Manley H, Detrick B, Katz

721		M, Cosgrove S, Rock C, Zyskind I, Silverberg JI, Rosenberg AZ, Duggal P, Manabe YC,
722		Collins MH, Heaney CD. 2021. Durability of SARS-CoV-2-specific IgG responses in saliva
723		for up to 8 months after infection.
724	46.	Mutambudzi M, Niedzwiedz CL, Macdonald EB, Leyland AH, Mair FS, Anderson JJ, Celis-
725		Morales CA, Cleland J, Forbes J, Gill JM, Hastie C, Ho FK, Jani BD, Mackay DF, Nicholl
726		BI, O'Donnell CA, Sattar NI, Welsh PI, Pell JP, Katikireddi SV, Demou E. 2020. Occupation
727		and risk of COVID-19: prospective cohort study of 120,621 UK Biobank participants.
728		medRxiv 2020.05.22.20109892.
729	47.	Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo C-G, Ma W, Mehta RS, Warner ET,
730		Sikavi DR, Lo C-H, Kwon S, Song M, Mucci LA, Stampfer MJ, Willett WC, Eliassen AH,
731		Hart JE, Chavarro JE, Rich-Edwards JW, Davies R, Capdevila J, Lee KA, Lochlainn MN,
732		Varsavsky T, Sudre CH, Cardoso MJ, Wolf J, Spector TD, Ourselin S, Steves CJ, Chan
733		AT, Albert CM, Andreotti G, Bala B, Balasubramanian BA, Beane-Freeman LE, Brownstein
734		JS, Bruinsma FJ, Coresh J, Costa R, Cowan AN, Deka A, Deming-Halverson SL, Elena
735		Martinez M, Ernst ME, Figueiredo JC, Fortuna P, Franks PW, Freeman LB, Gardner CD,
736		Ghobrial IM, Haiman CA, Hall JE, Kang JH, Kirpach B, Koenen KC, Kubzansky LD, Lacey,
737		Jr JV, Le Marchand L, Lin X, Lutsey P, Marinac CR, Martinez ME, Milne RL, Murray AM,
738		Nash D, Palmer JR, Patel AV, Pierce E, Robertson MM, Rosenberg L, Sandler DP,
739		Schurman SH, Sewalk K, Sharma SV, Sidey-Gibbons CJ, Slevin L, Smoller JW., Steves
740		CJ, Tiirikainen MI, Weiss ST, Wilkens LR, Zhang F. 2020. Risk of COVID-19 among front-
741		line health-care workers and the general community: a prospective cohort study. The
742		Lancet Public Health S246826672030164X.

743 48. Harris	PA, Taylor R, 1	Thielke R, I	Payne J,	Gonzalez N,	Conde JG.	2009. Research
----------------	-----------------	--------------	----------	-------------	-----------	----------------

- 744 electronic data capture (REDCap)--a metadata-driven methodology and workflow process
- for providing translational research informatics support. J Biomed Inform 42:377–381.
- 49. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G,
- 747 Delacqua F, Kirby J, Duda SN. 2019. The REDCap Consortium: Building an International
- 748 Community of Software Platform Partners. J Biomed Inform 95:103208.
- 50. R: The R Project for Statistical Computing. https://www.r-project.org/. Retrieved 18
- 750 October 2021.